Hormonal
Selective GSK-3 inhibitors (CHIR 98014, CHIR 99021) potentiate insulin-stimulated glucose transport and lower blood glucose in insulin-resistant states without causing hypoglycemia.
This research identifies a class of drugs (GSK-3 inhibitors) that can improve how insulin works in people with insulin resistance, helping to lower blood sugar without the risk of dangerous lows. While not a lifestyle intervention, it highlights that targeting specific enzymes can restore insulin sensitivity.
Single oral or subcutaneous doses of the inhibitors (30 – 48 mg/kg) rapidly lowered blood glucose levels and improved glucose disposal after oral or intravenous glucose challenges in ZDF rats and db/db mice, without causing hypoglycemia or markedly elevating insulin.
Why this rating
Strong in vitro and in vivo rodent data, but lacks human clinical trial data in this specific text.
Source
Selective Glycogen Synthase Kinase 3 Inhibitors Potentiate Insulin Activation of Glucose Transport and Utilization In Vitro and In Vivo
David B. Ring et al. · Diabetes · 2003
DOI 10.2337/diabetes.52.3.588
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →